Liquidia Corporation, a prominent biopharmaceutical firm operating within the United States, has recently committed itself to the development, manufacturing, and commercialization of numerous products in order to meet the pressing needs of patients. Among its most promising product candidates is YUTREPIA, an innovative inhaled dry powder formulation of treprostinil which holds great potential for the effective treatment of pulmonary arterial hypertension. The corporation also currently distributes generic treprostinil injection to patients throughout the region. Founded in 2004 and currently based in Morrisville, North Carolina, Liquidia Corporation is positioning itself as a leading contender in the biopharmaceutical industry.